Last year Sanofi boss Chris Viehbacher ran out his list of his favorite emerging market opportunities including Colombia, Indonesia and Vietnam. A new rundown on recent developments in Vietnam, show the many reasons why Viehbacher would see the southeast Asian country as a very good bet.
While Quintiles has been active in Indonesia since 2006, it has never been able to involve the country in a global clinical trial. That's all changing thanks to a partnership with Indonesia's Prodia Clinical Laboratory.
Asia is becoming a danger zone for pharma's intellectual property. On the heels of India's first compulsory licensing move, Indonesia has nixed patent protection on 7 HIV fighters and hepatitis drugs. The move would open the gates to cheap generic rivals, expanding access--and cutting into sales of pharma's brand names.
Merck ($MRK) has opened a $21 million packaging plant in Indonesia, expecting to tap growth in Asian markets.
Sanofi boss Chris Viehbacher isn't limiting his global drug giant's emerging market opportunities to China and India--or any of the four BRIC countries for that matter. In an interview with Bloomberg , the Sanofi CEO made known that he sees growth opportunities in spots such as Colombia, Indonesia and Vietnam.
Pfizer ($PFE) will expand in Indonesia ahead of government plans to offer health insurance for some low-income people.
Yusoff Rahman, CEO of generic drug manufacturer Pharmaniaga, confirmed the company has set aside $10 million to acquire an API plant in Indonesia.
Given the measly growth projections for U.S. and Europe, it's no surprise that expansion-minded drugmakers are looking eastward.
In another price-cutting move, GlaxoSmithKline has slashed the price tags on all its drugs in Indonesia by 30 percent to 50 percent, in a bid to increase sales volumes, Reuters reports. The new cuts
Everyone who's keeping even casual track of the drug industry knows that companies are relying on emerging markets to help fuel sales growth in the coming years as patents expire and growth in the